Efficacy and safety of nivolumab alone or in combination with ipilimumab in patients with mucosal melanoma: A pooled analysis

Journal of Clinical Oncology

Volumn 35, Issue 2, 2017, Pages 226-235

  D'Angelo, Sandra P ^a   Larkin, James ^b   Sosman, Jeffrey A ^d   Lebbé, Celeste ^e   Brady, Benjamin ^g   Neyns, Bart ^h   Schmidt, Henrik ⁱ   Hassel, Jessica C ^j   Hodi, F Stephen ^m   Lorigan, Paul ^c   Savage, Kerry J ⁿ   Miller, Wilson H ^o   Mohr, Peter ^k   Marquez Rodas, Ivan ^p   Charles, Julie ^f   Kaatz, Martin ^l   Sznol, Mario ^q   Weber, Jeffrey S ^r   Shoushtari, Alexander N ^a   Ruisi, Mary ^s   Jiang, Joel ^s   Wolchok, Jedd D ^a   more..

^a MEMORIAL SLOAN KETTERING CANCER CENTER   (United States)

^b ROYAL MARSDEN HOSPITAL   (United Kingdom)

^c UNIVERSITY OF MANCHESTER   (United Kingdom)

^d VANDERBILT UNIVERSITY MEDICAL CENTER   (United States)

^e INSERM   (France)

^f GRENOBLE UNIVERSITY HOSPITAL   (France)

^g CABRINI INSTITUTE   (Australia)

^h UNIVERSITY HOSPITAL BRUSSELS   (Belgium)

ⁱ AARHUS UNIVERSITY   (Denmark)

^j UNIVERSITY HOSPITAL HEIDELBERG   (Germany)

^k Elbe Kliniken   (Germany)

^l JENA UNIVERSITY HOSPITAL   (Germany)

^m DANA FARBER CANCER INSTITUTE   (United States)

ⁿ UNIVERSITY OF BRITISH COLUMBIA   (Canada)

^o MCGILL UNIVERSITY   (Canada)

^p HOSPITAL GENERAL UNIVERSITARIO GREGORIO MARAÑÓN   (Spain)

^q YALE UNIVERSITY SCHOOL OF MEDICINE   (United States)

^r H LEE MOFFITT CANCER CENTER AND RESEARCH INSTITUTE   (United States)

^s BRISTOL MYERS SQUIBB   (United States)

more..

Author keywords

[No Author keywords available]

Indexed keywords

ALANINE AMINOTRANSFERASE; AMYLASE; ASPARTATE AMINOTRANSFERASE; B RAF KINASE; IPILIMUMAB; LACTATE DEHYDROGENASE; NIVOLUMAB; TRIACYLGLYCEROL LIPASE; ANTINEOPLASTIC AGENT; MONOCLONAL ANTIBODY;

ABDOMINAL PAIN; ADULT; AGED; ALANINE AMINOTRANSFERASE BLOOD LEVEL; AMYLASE BLOOD LEVEL; ANEMIA; ARTHRALGIA; ARTICLE; ASPARTATE AMINOTRANSFERASE BLOOD LEVEL; ASTHENIA; BLURRED VISION; CANCER IMMUNOTHERAPY; CANCER OF UNKNOWN PRIMARY SITE; CANCER PATIENT; CANCER SURVIVAL; CHILL; COLITIS; COMBINATION DRUG THERAPY; CONSTIPATION; CONTROLLED CLINICAL TRIAL (TOPIC); CONTROLLED STUDY; COUGHING; CUTANEOUS MELANOMA; DECREASED APPETITE; DIARRHEA; DIZZINESS; DRUG EFFICACY; DRUG FATALITY; DRUG SAFETY; DRUG WITHDRAWAL; DYSPNEA; FATIGUE; FEMALE; FEVER; GENE MUTATION; HEADACHE; HUMAN; HYPERHIDROSIS; HYPERTHYROIDISM; HYPOPHYSITIS; HYPOTHYROIDISM; LACTATE DEHYDROGENASE BLOOD LEVEL; MACULOPAPULAR RASH; MAJOR CLINICAL STUDY; MALE; MONOTHERAPY; MUCOSAL MELANOMA; MYALGIA; NAUSEA; PAIN; PHASE 1 CLINICAL TRIAL (TOPIC); PHASE 2 CLINICAL TRIAL (TOPIC); PHASE 3 CLINICAL TRIAL (TOPIC); PNEUMONIA; PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL; PRURITUS; RASH; SIDE EFFECT; THYROIDITIS; TREATMENT RESPONSE; TRIACYLGLYCEROL LIPASE BLOOD LEVEL; TUMOR VOLUME; UVEA MELANOMA; VITILIGO; VOMITING; WEIGHT REDUCTION; XEROSTOMIA; MELANOMA; MUCOSA;

AGED; ANTIBODIES, MONOCLONAL; ANTINEOPLASTIC AGENTS; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; FEMALE; HUMANS; MALE; MELANOMA; MUCOUS MEMBRANE;

EID: 85009926954     PISSN: 0732183X     EISSN: 15277755     Source Type: Journal    
DOI: 10.1200/JCO.2016.67.9258     Document Type: Article

References (28)

1. Postow MA, Callahan MK, Wolchok JD: Immune checkpoint blockade in cancer therapy. J Clin Oncol 33:1974-1982, 2015
2. Schadendorf D, Hodi FS, Robert C, et al: Pooled analysis of long-term survival data from phase II and phase III trials of ipilimumab in unresectable or metastatic melanoma. J Clin Oncol 33:1889-1894, 2015
3. Robert C, Long GV, Brady B, et al: Nivolumab in previously untreated melanoma without BRAF mutation. N Engl J Med 372:320-330, 2015
4. Weber JS, D'Angelo SP, Minor D, et al: Nivolumab versus chemotherapy in patients with advanced melanoma who progressed after anti-CTLA-4 treatment (CheckMate 037): A randomized, controlled, open-label, phase 3 trial. Lancet Oncol 16: 375-384, 2015
5. Postow MA, Chesney J, Pavlick AC, et al: Nivolumab and ipilimumab versus ipilimumab in untreated melanoma. N Engl J Med 372:2006-2017, 2015
6. Larkin J, Chiarion-Sileni V, Gonzalez R, et al: Combined nivolumab and ipilimumab or monotherapy in untreated melanoma. N Engl J Med 373: 23-34, 2015
7. Ahmad SS, Qian W, Ellis S, et al: Ipilimumab in the real world: The UK expanded access programme experience in previously treated advanced melanoma patients. Melanoma Res 25:432-442, 2015
8. Tas F, Keskin S, Karadeniz A, et al: Noncutaneous melanoma have distinct features from each other and cutaneous melanoma. Oncology 81: 353-358, 2011
9. Mihajlovic M, Vlajkovic S, Jovanovic P, et al: Primary mucosal melanomas: A comprehensive review. Int J Clin Exp Pathol 5:739-753, 2012
10. DeMatos P, Tyler DS, Seigler HF: Malignant melanoma of the mucous membranes: A review of 119 cases. Ann Surg Oncol 5:733-742, 1998
11. Wang X, Si L, Guo J: Treatment algorithm of metastatic mucosal melanoma. Chin Clin Oncol 3:38, 2014
12. Bitas C, Shoushtari AN, Bluth MJ, et al: The Memorial Sloan Kettering Cancer Center (MSKCC) experience of systemic therapy in mucosal melanoma. J Clin Oncol 32:5s, 2014 (suppl 5s; abstr 9073)
13. Yi JH, Yi SY, Lee HR, et al: Dacarbazine-based chemotherapy as first-line treatment in noncutaneous metastatic melanoma: Multicenter, retrospective analysis in Asia. Melanoma Res 21:223-227, 2011
14. Carvajal RD, Antonescu CR, Wolchok JD, et al: KIT as a therapeutic target in metastatic melanoma. JAMA 305:2327-2334, 2011
15. Hodi FS, Corless CL, Giobbie-Hurder A, et al: Imatinib for melanomas harboring mutationally activated or amplified KIT arising on mucosal, acral, and chronically sun-damaged skin. J Clin Oncol 31: 3182-3190, 2013
16. Postow MA, Luke JJ, Bluth MJ, et al: Ipilimumab for patients with advanced mucosal melanoma. Oncologist 18:726-732, 2013
17. Alexander M, Mellor JD, McArthur G, et al: Ipilimumab in pretreated patients with unresectable or metastatic cutaneous, uveal and mucosal melanoma. Med J Aust 201:49-53, 2014
18. Del Vecchio M, Di Guardo L, Ascierto PA, et al: Efficacy and safety of ipilimumab 3mg/kg in patients with pretreated, metastatic, mucosal melanoma. Eur J Cancer 50:121-127, 2014
19. Zimmer L, Eigentler TK, Kiecker F, et al: Openlabel, multicenter, single-arm phase II DeCOG-study of ipilimumab in pretreated patients with different subtypes of metastatic melanoma. J Transl Med 13: 351, 2015
20. Min L, Hodi FS: Anti-PD1 following ipilimumab for mucosal melanoma: Durable tumor response associated with severe hypothyroidism and rhabdomyolysis. Cancer Immunol Res 2:15-18, 2014
21. Topalian SL, Sznol M, McDermott DF, et al: Survival, durable tumor remission, and long-term safety in patients with advanced melanoma receiving nivolumab. J Clin Oncol 32:1020-1030, 2014
22. Urba WJ, Martin-Algarra S, Callahan M, et al: Immunomodulatory activity of nivolumab monotherapy in patients with advanced melanoma. Presented at Am Assoc Cancer Res Annual Meeting, Philadelphia, PA, April 18-22, 2015 (abstr 2855)
23. Wolchok JD, Kluger H, Callahan MK, et al: Nivolumab plus ipilimumab in advanced melanoma. N Engl J Med 369:122-133, 2013
24. Del Prete V, Chaloupka K, Holzmann D, et al: Noncutaneous melanomas: A single-center analysis. Dermatology 232:22-29, 2016
25. Curtin JA, Fridlyand J, Kageshita T, et al: Distinct sets of genetic alterations in melanoma. N Engl J Med 353:2135-2147, 2005
26. Furney SJ, Turajlic S, Stamp G, et al: Genome sequencing of mucosal melanomas reveals that they are driven by distinct mechanisms from cutaneous melanoma. J Pathol 230:261-269, 2013
27. Bastian BC: The molecular pathology of melanoma: An integrated taxonomy of melanocytic neoplasia. Annu Rev Pathol 9:239-271, 2014
28. Larkin J, Lao CD, Urba WJ, et al: Efficacy and safety of nivolumab in patients with BRAF V600 mutant and BRAF wild-type advanced melanoma: A pooled analysis of 4 clinical trials. JAMA Oncol 1: 433-440, 2015